This is an aggregated industry headline. Read the full story at BioPharma Dive →
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
By BioPharma Dive
· Jun 29, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a "n…
The WeekFierceBiotech ↗
The FDA has delayed a decision on the approval of Praxis Precision Medicine's rare epilepsy prospect by three …
The WeekBriefing
The FDA’s June 2026 update again highlights brand drugs still lacking generic challengers, aiming to spur ANDA…